ivWatch Positioned for Market Entry with Australian and European Patent Grants

ivWatch leaps to 17 global patents protecting their innovative technologies

NEWPORT NEWS, Va., June 27, 2019 – ivWatch, a biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, expands their foothold in Australia and Europe by securing two patent grants for core product technologies. Additionally, the ivWatch European Patent No. 2830488 announced in October 2018 has been validated in six nations resulting in the following rights:

  • Belgium Patent No. EP2830488
  • Switzerland Patent No. EP2830488
  • Germany Patent No. 602013042197.8
  • France Patent No. EP2830488
  • United Kingdom Patent No. EP2830488
  • Netherlands Patent No. EP2830488

“Whether it be because of central line infection risks, or industry guidance advising against unnecessary placement of peripherally inserted central catheter (PICC) lines, we’re seeing a global shift to the use of more peripheral IVs, or short peripheral catheters, for drug and fluid delivery,” said Gary Warren, president and CEO of ivWatch. “Protecting this technology worldwide ensures medical professionals are certain they are providing highly effective patient monitoring during IV therapy administration.”

The granting of Australian Patent No. 2018211312 is for a technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, known as receptacles, can be either independent of the infusion site dressings or integrated within.

The patent bringing the company’s intellectual property (IP) patent portfolio to 17 is European Patent No. 2830487, for mitigating the effects of tissue blood volume changes. This patent describes methods used by ivWatch to extract meaningful signals from biosensors when patients are moving. By mitigating the effects of changing tissue blood volume, the system minimizes “false” alerts. This patent is being validated in several European nations who have shown significant interest in surveillance monitoring for patients receiving medications through peripheral IVs.

View the full patent portfolio at www.ivWatch.com/patents or to learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Office (855) 489-2824 x7007, Mobile (757) 660-4949

JAVA Study: Evaluating ivWatch Technology in Pediatric IV Sites

Benefits cited include early recognition of infiltration, avoidance of serious injuries, and potential reduction in litigation

NEWPORT NEWS, Va., June 25, 2019 – A new study in the peer-reviewed Journal of the Association for Vascular Access (JAVA) examines several important metrics that describe the performance of the ivWatch Model 400 at a leading children’s hospital in Ohio. The key finding of the pilot study was the device detected a peripheral IV infiltration 80 percent of the time before the clinician detected the leakage event.

Data was collected on 156 patients where the ivWatch Model 400 was incorporated into IV therapy but did not notify clinicians of infiltration, and then compared to data on 57 patients where the ivWatch Model 400 notified clinicians via audible and visual alerts about infiltration events. This allowed investigators to analyze how the ivWatch Model 400 compared to clinicians’ assessments in the early detection of IV infiltration. Success was measured by the frequency of infiltration events and how often the device issued notifications.

The study, which appears in the Summer 2019 issue of JAVA, showed that on average the device issued a notification signaling a possible infiltration (Yellow Check IV) 32.3 hours prior to a clinician detecting it, while a notification signaling a probable infiltration (Red Check IV) was issued an average of 29.8 hours prior to clinician detection. It was also concluded by the authors of the study at Cincinnati Children’s Hospital, “technology that provides early detection of IV infiltrations may be advantageous for the patient, clinician, and institution.”

This pilot study was undertaken in part because of the medical center’s commitment to patient safety including efforts to reduce severe and moderate peripheral IV infiltration and extravasation occurrences. The results underline the practice of using an additional intervention in conjunction with following industry recommendations of IV site assessment to promote the earliest possible identification of this common complication of IV therapy.

The study titled “The Use of Optical Detection for Continuous Monitoring of Pediatric IV Sites” was authored by Darcy Doellman, MSN, RN, CRNI, VA-BC and Sylvia Rineair, MSHA, BSN, RN, VA-BC. The abstract can be viewed at https://www.avajournal.com/doi/abs/10.2309/j.java.2019.002.003, and the article citation is:

  • Darcy Doellman and Sylvia Rineair (2019) The Use of Optical Detection for Continuous Monitoring of Pediatric IV Sites. Journal of the Association for Vascular Access: Summer 2019, Vol. 24, No. 2, pp. 44-47.

To learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Office (855) 489-2824 x7007, Mobile (757) 660-4949


In the News: Companies Combating IV Infiltrations

Patient Safety & Quality Healthcare (PSQH) discussed IV infiltration and it’s potential for life-threatening consequences in a recent article. The piece, “Companies Work to Help Combat IV Infiltrations” includes commentary from ivWatch President and CEO, Gary Warren, and cites the ivWatch Model 400 as a clinician partner helping to deliver improved patient care with constant monitoring of the IV site. Read the full article here.

In the News: ivWatch Sponsored ISAVE That Podcast Episode

Season 2 Episode 7 of the Association for Vascular Access ‘ISAVE That Podcast’ is sponsored by ivWatch. A myIV.com Patient Spotlight story about a severe pediatric infiltration injury was featured in an interview during the episode segment ‘Beyond the Manuscript.” Listen to the full episode here.

ivWatch Announces Expansion into Canada with Distributor Roxon

HAMPTON, Va., May 7, 2019 – ivWatch, a leading provider of biosensor technology focused on improving patient safety and the effectiveness of intravenous (IV) therapy, has entered into an exclusive distribution agreement with Roxon medi-tech, a distributor of specialized medical equipment based in Montreal, Quebec. The agreement includes the rights to distribute the ivWatch Model 400, the only device to receive clearance, globally, to offer early detection of infiltrations/extravasations, in the Canadian market.

“Many health systems and children’s hospitals in Canada have recognized peripheral IV infiltration as a serious safety event,” said Scott Hensley, executive vice president of sales and business development at ivWatch. “Providing access to ivWatch technology in collaboration with Roxon strengthens our international reach, which continues to be a core priority for the company.”

Every infiltration is a medication dosing and delivery error that can impact the patient through prolonged hospital stays, temporary harm or permanent injuries. The team at Roxon intends to leverage their long-standing industry networks to educate on the prevalence of IV failures and the importance of surveillance monitoring to improve patient safety.

“We’re ready to expand on the market excitement as we usher the ivWatch breakthrough technology movement to our large network of Canadian clinicians,” said Roxon President Michael Solomita. “Our deep market expertise combined with adding this innovative product to our portfolio complements our mission of providing the safest medical devices with the highest industry standards to patients throughout the country.”

ivWatch has previously announced the issuance of a medical device license (MDL) by Health Canada permitting the company to sell the ivWatch Model 400 to Canadian health care organizations, as well as achieving ISO 13485 Certification, the global standard for medical device quality management systems (QMS) developed by the International Organization for Standardization (ISO®).

“With more than a billion IV catheters sold globally every year, the drug delivery errors caused by IV infiltration and extravasation urgently needs to be addressed,” said Gary Warren, president and CEO of ivWatch. “Delivering ivWatch technology to health care systems outside the U.S. that are actively looking for a solution is crucial for addressing this huge unmet need in vascular access. Working with our distribution partners, we can reach more patients and assist institutions worldwide with keeping patients safe from preventable harm.”

To learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

In the News: ivWatch CEO on ‘The Future of Healthcare’

ivWatch President and CEO Discusses Improving Quality of Care

ivWatch President and CEO Gary Warren was interviewed for the series “Future of Healthcare,” to analyze what improvements must be made to deliver better care at a lower cost. Warren reviews his own patient journey and how the ivWatch company mission became personal. The questions posed are responded to with an overview of the challenges when creating a market for a new medical technology, and the rewards of extending the ivWatch technology to more patients by starting a patient safety movement within hospital walls.

He closes with how improving drug efficacy is a matter of life and death for the critically ill or injured patient. Read the full Medium/Authority Magazine interview here.

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest